cardiorpharmaceuticals
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA International
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA Breaking News
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら